10x Genomics (TXG) Other Non-Current Liabilities (2018 - 2026)

10x Genomics' Other Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities fell 77.36% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $1.2 million (down 77.36% YoY), while the FY2025 annual figure was $1.2 million, down 75.4% from the prior year.
• Other Non-Current Liabilities came in at $1.2 million for Q1 2026 at 10x Genomics, down from $1.2 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $10.1 million in Q3 2023 to a low of $1.2 million in Q1 2026.
• A 5-year average of $5.6 million and a median of $5.4 million in 2025 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities jumped 77.04% in 2023 and plunged 77.36% in 2026, its largest moves.
• 10x Genomics' Other Non-Current Liabilities stood at $3.0 million in 2022, then soared by 43.65% to $4.3 million in 2023, then grew by 17.64% to $5.0 million in 2024, then slumped by 75.4% to $1.2 million in 2025, then slipped by 1.21% to $1.2 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $1.2 million, $1.2 million, and $6.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison